Jason W Wen1,2, Michael A Kohn3, Robert Wong4, Ma Somsouk5, Mandana Khalili5,6, Jacquelyn Maher5,6, Michele M Tana5,6. 1. Augusta University, Augusta, Georgia, USA. 2. Emory University School of Medicine, Atlanta, Georgia, USA. 3. UCSF Department of Epidemiology and Biostatistics, San Francisco, California, USA. 4. Alameda Health Systems-Highland Hospital, Oakland, California, USA. 5. UCSF Department of Medicine, San Francisco, California, USA. 6. UCSF Liver Center, San Francisco, California, USA.
Abstract
OBJECTIVES: The healthcare burden of autoimmune hepatitis (AIH) in the United States has not been characterized. We previously showed that AIH disproportionately affects people of color in a single hospital system. The current study aimed to determine whether the same disparity occurs nationwide. METHODS: We analyzed hospitalizations with a primary discharge diagnosis corresponding to the ICD-9 code for AIH in the National Inpatient Sample between 2008 and 2012. For each racial/ethnic group, we calculated the AIH hospitalization rate per 100,000 population and per 100,000 all-cause hospitalizations, then calculated a risk ratio compared to the reference rate among whites. We used multivariable logistic regression models to assess for racial disparities and to identify predictors of in-hospital mortality during AIH hospitalizations. RESULTS: The national rate of AIH hospitalization was 0.73 hospitalizations per 100,000 population. Blacks and Latinos were hospitalized for AIH at a rate 69% (P<0.001) and 20% higher (P<0.001) than whites, respectively. After controlling for age, gender, payer, residence, zip code income, region, and cirrhosis, black race was a statistically significant predictor for mortality during AIH hospitalizations (odds ratio (OR) 2.81, 95% confidence interval (CI) 1.43, 5.47). CONCLUSIONS: Hospitalizations for AIH disproportionately affect black and Latino Americans. Black race is independently associated with higher odds of death during hospitalizations for AIH. This racial disparity may be related to biological, genetic, environmental, socioeconomic, and healthcare access and quality factors.
OBJECTIVES: The healthcare burden of autoimmune hepatitis (AIH) in the United States has not been characterized. We previously showed that AIH disproportionately affects people of color in a single hospital system. The current study aimed to determine whether the same disparity occurs nationwide. METHODS: We analyzed hospitalizations with a primary discharge diagnosis corresponding to the ICD-9 code for AIH in the National Inpatient Sample between 2008 and 2012. For each racial/ethnic group, we calculated the AIH hospitalization rate per 100,000 population and per 100,000 all-cause hospitalizations, then calculated a risk ratio compared to the reference rate among whites. We used multivariable logistic regression models to assess for racial disparities and to identify predictors of in-hospital mortality during AIH hospitalizations. RESULTS: The national rate of AIH hospitalization was 0.73 hospitalizations per 100,000 population. Blacks and Latinos were hospitalized for AIH at a rate 69% (P<0.001) and 20% higher (P<0.001) than whites, respectively. After controlling for age, gender, payer, residence, zip code income, region, and cirrhosis, black race was a statistically significant predictor for mortality during AIH hospitalizations (odds ratio (OR) 2.81, 95% confidence interval (CI) 1.43, 5.47). CONCLUSIONS: Hospitalizations for AIH disproportionately affect black and Latino Americans. Black race is independently associated with higher odds of death during hospitalizations for AIH. This racial disparity may be related to biological, genetic, environmental, socioeconomic, and healthcare access and quality factors.
Authors: William J Hall; Mimi V Chapman; Kent M Lee; Yesenia M Merino; Tainayah W Thomas; B Keith Payne; Eugenia Eng; Steven H Day; Tamera Coyne-Beasley Journal: Am J Public Health Date: 2015-10-15 Impact factor: 9.308
Authors: F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya Journal: J Hepatol Date: 1999-11 Impact factor: 25.083
Authors: Daniel Kim; Daniel Eshtiaghpour; Joel Alpern; Anuj Datta; Viktor E Eysselein; Hal F Yee Journal: BMC Gastroenterol Date: 2015-07-28 Impact factor: 3.067
Authors: Vanessa L Kronzer; Alex D Tarabochia; Angie S Lobo Romero; Nicholas Y Tan; Thomas J O'Byrne; Cynthia S Crowson; Tamiel N Turley; Elena Myasoedova; John M Davis; Claire E Raphael; Rajiv Gulati; Sharonne N Hayes; Marysia S Tweet Journal: J Am Coll Cardiol Date: 2020-11-10 Impact factor: 24.094
Authors: Therese Bittermann; Nadim Mahmud; James D Lewis; Cynthia Levy; David S Goldberg Journal: Pharmacoepidemiol Drug Saf Date: 2021-05-21 Impact factor: 2.732
Authors: Nahel A Tunio; Emad Mansoor; Mohammed Z Sheriff; Gregory S Cooper; Seth N Sclair; Stanley M Cohen Journal: J Clin Gastroenterol Date: 2021 Nov-Dec 01 Impact factor: 3.062